NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Sacituzumab govitecan|DRUG: Pembrolizumab
Sponsor: West German Study Group
Collaborators: Gilead Sciences|Merck Sharp & Dohme LLC